Maven Securities LTD Acquires Shares of 30,000 Nurix Therapeutics, Inc. $NRIX

Maven Securities LTD acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the fourth quarter, Holdings Channel.com reports. The fund acquired 30,000 shares of the company’s stock, valued at approximately $569,000.

Other large investors have also recently made changes to their positions in the company. Larson Financial Group LLC raised its holdings in shares of Nurix Therapeutics by 339.0% in the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after purchasing an additional 1,190 shares during the last quarter. Intesa Sanpaolo Wealth Management bought a new position in shares of Nurix Therapeutics during the fourth quarter valued at about $31,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Nurix Therapeutics during the fourth quarter valued at about $33,000. Wexford Capital LP bought a new position in shares of Nurix Therapeutics during the third quarter valued at about $41,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Nurix Therapeutics by 118.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after purchasing an additional 3,475 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. BTIG Research raised their price target on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Truist Financial raised their price target on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Jefferies Financial Group raised their price target on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, June 8th. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, June 10th. Finally, Wells Fargo & Company lowered shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and dropped their price target for the company from $28.00 to $25.00 in a research report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.14.

Nurix Therapeutics Stock Performance

NASDAQ NRIX opened at $17.04 on Tuesday. Nurix Therapeutics, Inc. has a 52-week low of $8.19 and a 52-week high of $22.50. The company has a 50-day simple moving average of $16.45 and a 200 day simple moving average of $16.91. The company has a market capitalization of $1.76 billion, a PE ratio of -5.39 and a beta of 1.86.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.The company had revenue of $6.25 million for the quarter, compared to analysts’ expectations of $14.25 million. As a group, analysts forecast that Nurix Therapeutics, Inc. will post -2.88 EPS for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 14,055 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the completion of the sale, the chief financial officer owned 37,592 shares in the company, valued at approximately $624,027.20. This trade represents a 27.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 3,214 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $16.65, for a total transaction of $53,513.10. Following the sale, the insider owned 120,399 shares of the company’s stock, valued at $2,004,643.35. This trade represents a 2.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 19,657 shares of company stock valued at $326,586 in the last 90 days. 6.70% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.